[ad_1] The FDA approval of Biogen’s Aduhelm for Alzheimer’s has breathed new life into neurology units across...
Alzheimers
[ad_1] Analysts hound Biogen with questions over Aduhelm’s $56K price point as news of Alzheimer’s OK ripples...
[ad_1] In this week’s “First Opinion Podcast,” I speak with Alzheimer’s expert Jason Karlawish, director of Penn’s...
